Economic Outcomes Associated with Switching Individuals with Schizophrenia Between Risperidone and Olanzapine: Findings from a Large US Claims Database

Author： Zhao Z.   Namjoshi M.   Barber B.L.   Loosbrock D.L.   Tunis S.L.   Zhu B.   Breier A.  

Publisher： Adis International

ISSN： 1172-7047

Source： CNS Drugs, Vol.18, Iss.3, 2004-01, pp. : 157-164

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Olanzapine versus Risperidone: A Prospective Comparison of Clinical and Economic Outcomes in Schizophrenia

By Edgell E.T.  

PharmacoEconomics, Vol. 18, Iss. 6, 2000-12 ,pp. : 567-579

Adis International

Access to resources Recommend Favorite

Switching Patients with Stable Schizophrenia or Schizoaffective Disorder from Olanzapine to Risperidone Long-Acting Injectable

By Rosa Fernanda  

Clinical Drug Investigation, Vol. 32, Iss. 4, 2012-04 ,pp. : 267-279

Adis International

Access to resources Recommend Favorite

Economic Outcomes Associated with Microvascular Complications of Type 2 Diabetes Mellitus: Results from a US Claims Data Analysis

By Pelletier Elise M.  

PharmacoEconomics, Vol. 27, Iss. 6, 2009-06 ,pp. : 479-490

Adis International

Access to resources Recommend Favorite

Olanzapine and risperidone on a par in schizophrenia

By  

Inpharma, Vol. 1, Iss. 1240, 2000-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Olanzapine and risperidone on a par in schizophrenia

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 265, 2000-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite